Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 13,908 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Blepharospasm
Interventions: incobotulinumtoxinA (Xeomin), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer's Disease
Interventions: Azeliragon, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 80
States / cities: Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 67 more

Conditions: Carpal Tunnel
Interventions: Narcotic, non-narcotic; Drug
Lead sponsor: Horizon Health Network; Other
Eligibility: 18 Years to 90 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Sioux Falls, South Dakota • Roanoke, Virginia

Conditions: Alzheimer's Disease
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Smoking Cessation
Interventions: Bupropion, Zonisamide, Placebo bupropion, Placebo zonisamide, E-cigarette; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Depression During Pregnancy
Interventions: Virtual reality behavioral activation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV (Human Immunodeficiency Virus), Pain
Interventions: Auricular Point Acupressure, Sham Auricular Point Acupressure; Other
Lead sponsor: Dan Song; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Urethral Stricture
Interventions: Optilume Drug Coated Balloon (DCB), Control Treatment; Device
Lead sponsor: Urotronic Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Daytona Beach, Florida + 17 more

Conditions: Schizophrenia
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: David Feifel; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Child Behavior Problem, Preterm, Parent-Child Relations, Parenting
Interventions: I-InTERACT Parenting Intervention (I2P) and coaching sessions, I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions, Internet Resources; Behavioral · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 8 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Depressive Disorder
Interventions: Saredutant succinate (SR48968C); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Obesity
Interventions: SHINE; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Smartphone-delivered CBT for MDD; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Food Preferences
Interventions: Behavioral economic intervention of online purchasing at a food pantry; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Arimoclomol, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Boston, Massachusetts

Conditions: Clostridium Difficile Infection
Interventions: Placebo, CRS3123; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Antimicrobial Prescribing Practices
Interventions: Academic Detailing by the Antimicrobial Utilization Team (AUT); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 785 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Exercise, Physical Activity, Healthy Adult, Interoception, Affect and Exertion During and Post-exercise
Interventions: Eyes-Closed Interoceptive Aerobic Exercise, Matched Eyes-Open Treadmill Exercise; Behavioral
Lead sponsor: Old Dominion University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Preeclampsia, Hypertension in Pregnancy
Interventions: Labetalol, Nifedipine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions: Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Transplantation
Interventions: Tisseelä fibrin sealant; Device
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: Not listed
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Depression
Interventions: Memantine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Non-adaptive Floreo VR control, Floreo Virtual Reality application; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 16 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcoholism, Alcohol Withdrawal
Interventions: Baclofen, Placebo; Drug
Lead sponsor: Essentia Health; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Duluth, Minnesota • Fargo, North Dakota

Search by objective public record fields.

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Narcotic vs. Non-narcotic Pain Study Protocol

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Virtual Reality-enhanced Psychotherapy for Perinatal Depression

Auricular Point Acupressure for Pain

ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

Oxytocin Add on Study for Stable Schizophrenic Patients

I-InTERACT Preterm Parenting

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)

A Trial of Behavioral Economic Interventions Among Food Pantry Clients

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

The Impact of an Antimicrobial Utilization Program on Antimicrobial Use

Eyes-Closed Interoceptive Aerobic Exercise Compared With Matched Eyes-Open Treadmill Exercise in Healthy Adults

Preeclampsia Postpartum Antihypertensive Treatment

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

Fibrin Sealant in Renal Transplantation

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Preventing Alcohol Withdrawal With Oral Baclofen